source
- Assertio accepts new buyout bid; AI biotech Isomorphic banks $2BAssertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.BioPharma Dive · 3mo ago↗ source
- FDA Approval Insights: Brexu-Cel for Relapsed/Refractory MCL: With Luhua (Michael) Wang, MDLuhua (Michael) Wang, MD, discusses the implications of the FDA approval of brexu-cel for the treatment of adult patients with relapsed/refractory MCL.onclive · 3mo ago↗ source
- Behind Galapagos’ transformation into Lakefront BiotherapeuticsCHICAGO — From a 22nd-floor office overlooking the Chicago Riverwalk, in the heart of the Midwest hub’s white-collar downtown district, Lakefront Biotherapeutics’ executives hope to stage the compa…